Powered by Atman Health
Blog

Notes from the Practice

Patients arrive with specific questions — about Lp(a), CAC scores, ApoB, family-history risk, lifestyle plateaus, the cholesterol therapy pipeline. Many of those questions deserve a longer answer than a fifteen-minute visit can hold.

These posts are where I write the longer answer. They follow the evidence, name the studies, and call out where the contrarian arguments have a point and where they don't. Written for the patient who already has the labs and wants to think through what they mean.

Posts are written by Rahul C. Deo, MD, PhD — a cardiologist and co-founder of Atman Health.

More: Substack · Atman Health · LinkedIn · Google Scholar

August 4, 2026

The other half of your heart

Everything most prevention advice covers is the arteries. The heart muscle stiffens on its own schedule, in people whose arteries are fine, and it is measurable years before symptoms. What to measure, and what the evidence supports doing about it.

Read more →
August 2, 2026

Reversing plaque: how far cholesterol has to fall, and why the calcium score rises

Coronary plaque can be reduced, and the calcium score often rises while it happens. What the imaging trials actually measured, how low the evidence supports going, and which number is worth following over decades.

Read more →
July 23, 2026

Dementia, your heart, and the APOE gene

More patients are worried about dementia than their hearts. Blood pressure control has randomized trials showing it lowers dementia risk; the cholesterol link is real but inferential; and the APOE gene everyone fears is a cholesterol-transport gene.

Read more →
July 23, 2026

Particle number: counting LDL instead of weighing it

LDL particle number, small dense LDL and a pattern letter of A or B. What the evidence supports, why much of the apparent discordance with LDL cholesterol turns out to be arithmetic, and the order worth testing in.

Read more →
July 22, 2026

Cholesterol balance: production, absorption, and which drug should work

A Cholesterol Balance panel sorts you into Over Producer, Balanced, or Over Absorber. It is not a risk score, the formula behind it is not published, and the one decision it can inform is whether ezetimibe is likely to help you.

Read more →
July 21, 2026

Fatty acids and the heart: beyond the omega-3 index

A fatty acid panel flags your omega-3 index, EPA, and DHA, each green, yellow, or red. The trials are genuinely split, the target is soft, and the practical question is how to use the panel without over-reading it.

Read more →
June 21, 2026

Statins: the arguments you've heard, and what the evidence actually shows

The five common social-media arguments against statins, and what the trials actually show. What is settled, where the nuance lives, and the modern lipid toolkit beyond just statins.

Read more →
June 14, 2026

GLP-1, SGLT2, and the heart: what the trials revealed about weight and cardiovascular risk

Cardiology has been surprised by what the GLP-1 and SGLT2 cardiovascular outcome trials revealed. The cardiac diseases that travel with weight, and what weight loss alone won't finish.

Read more →
June 13, 2026

The perils of standing still

How preventive cardiology has changed over twenty years, and why too many patients are still getting the 2008 version of the conversation.

Read more →
June 7, 2026

A new pattern for cardiology visits

Labs and imaging reports in hand, LLM-driven self-analysis, and no PCP involved. A new pattern of how patients are arriving for cardiology care.

Read more →
June 4, 2026

Lp(a) therapies: what we have today, and what's coming

No FDA-approved Lp(a)-specific therapy exists yet. But four drugs in late-stage trials may change that in 2026–2028. What to do today, and what's worth waiting for.

Read more →
June 4, 2026

Diet, cholesterol, and the saturated fat controversy

Saturated fat raises LDL. LDL causes heart disease. The contrarian arguments are mostly wrong, but not entirely, and the nuance matters. What the evidence actually says.

Read more →
May 23, 2026

The new cholesterol guidelines: Lp(a), ApoB, and treating at lower thresholds

The 2026 ACC/AHA dyslipidemia guidelines lowered treatment thresholds, expanded the toolkit beyond statins, and elevated Lp(a) and ApoB. What it means for patients.

Read more →
May 23, 2026

Cleerly, CCTA, and calcium scores: which heart test, when?

Patients ask about Cleerly scans constantly. When CT coronary angiography and AI-quantified plaque scans actually change care — and when they don't.

Read more →
November 4, 2025

How does virtual cardiology work?

There's a nationwide shortage of cardiologists and months-long waits. Almost all cardiology problems short of a procedure can be handled well by telehealth.

Read more →